These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 10705918)

  • 1. The ErbB receptors as targets for breast cancer therapy.
    Albanell J; Baselga J
    J Mammary Gland Biol Neoplasia; 1999 Oct; 4(4):337-51. PubMed ID: 10705918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Type I receptor tyrosine kinases as targets for therapy in breast cancer.
    Baselga J; Mendelsohn J
    J Mammary Gland Biol Neoplasia; 1997 Apr; 2(2):165-74. PubMed ID: 10882302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The EGF receptor family as targets for cancer therapy.
    Mendelsohn J; Baselga J
    Oncogene; 2000 Dec; 19(56):6550-65. PubMed ID: 11426640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibodies directed against Lewis-Y antigen inhibit signaling of Lewis-Y modified ErbB receptors.
    Klinger M; Farhan H; Just H; Drobny H; Himmler G; Loibner H; Mudde GC; Freissmuth M; Sexl V
    Cancer Res; 2004 Feb; 64(3):1087-93. PubMed ID: 14871842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticancer therapy targeting the erbB family of receptor tyrosine kinases.
    Slichenmyer WJ; Fry DW
    Semin Oncol; 2001 Oct; 28(5 Suppl 16):67-79. PubMed ID: 11706398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.
    Emens LA
    Am J Ther; 2005; 12(3):243-53. PubMed ID: 15891269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ErbB receptor family: a therapeutic target for cancer.
    de Bono JS; Rowinsky EK
    Trends Mol Med; 2002; 8(4 Suppl):S19-26. PubMed ID: 11927283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The FUTURE of ErbB-1 and ErbB-2 pathway inhibition in breast cancer: targeting multiple receptors.
    Slamon DJ
    Oncologist; 2004; 9 Suppl 3():1-3. PubMed ID: 15163840
    [No Abstract]   [Full Text] [Related]  

  • 9. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.
    Subramaniam D; He AR; Hwang J; Deeken J; Pishvaian M; Hartley ML; Marshall JL
    Curr Cancer Drug Targets; 2015; 14(9):775-93. PubMed ID: 25435079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined anti-EGF receptor and anti-HER2 receptor therapy in breast cancer: a promising strategy ready for clinical testing.
    Baselga J
    Ann Oncol; 2002 Jan; 13(1):8-9. PubMed ID: 11863116
    [No Abstract]   [Full Text] [Related]  

  • 11. Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment.
    Normanno N; Bianco C; De Luca A; Maiello MR; Salomon DS
    Endocr Relat Cancer; 2003 Mar; 10(1):1-21. PubMed ID: 12653668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas.
    Larbouret C; Robert B; Navarro-Teulon I; Thèzenas S; Ladjemi MZ; Morisseau S; Campigna E; Bibeau F; Mach JP; Pèlegrin A; Azria D
    Clin Cancer Res; 2007 Jun; 13(11):3356-62. PubMed ID: 17545543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel engineered trastuzumab conformational epitopes demonstrate in vitro and in vivo antitumor properties against HER-2/neu.
    Garrett JT; Rawale S; Allen SD; Phillips G; Forni G; Morris JC; Kaumaya PT
    J Immunol; 2007 Jun; 178(11):7120-31. PubMed ID: 17513761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.
    Schwarz LJ; Hutchinson KE; Rexer BN; Estrada MV; Gonzalez Ericsson PI; Sanders ME; Dugger TC; Formisano L; Guerrero-Zotano A; Red-Brewer M; Young CD; Lantto J; Pedersen MW; Kragh M; Horak ID; Arteaga CL
    J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER2 as a target for breast cancer therapy.
    Tagliabue E; Balsari A; Campiglio M; Pupa SM
    Expert Opin Biol Ther; 2010 May; 10(5):711-24. PubMed ID: 20214497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu).
    Reid A; Vidal L; Shaw H; de Bono J
    Eur J Cancer; 2007 Feb; 43(3):481-9. PubMed ID: 17208435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4.
    Albanell J; Codony J; Rovira A; Mellado B; Gascón P
    Adv Exp Med Biol; 2003; 532():253-68. PubMed ID: 12908564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer.
    Gonzalez-Angulo AM; Hortobágyi GN; Esteva FJ
    Oncologist; 2006 Sep; 11(8):857-67. PubMed ID: 16951389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group.
    Shak S
    Semin Oncol; 1999 Aug; 26(4 Suppl 12):71-7. PubMed ID: 10482196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth factor receptors in breast cancer: potential for therapeutic intervention.
    Nahta R; Hortobágyi GN; Esteva FJ
    Oncologist; 2003; 8(1):5-17. PubMed ID: 12604728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.